Overall, SGLT2 inhibitors show promising efficacy in patients with MASH by reducing hepatic lipid accumulation, but more histological evidence is needed to confirm the benefits of SGLT2 inhibitors in hepatic steatosis. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.